About the Authors

Ahmed E. Enayetallah

Ahmed.Enayetallah@pfizer.com

Affiliation Compound Safety Prediction Group, Pfizer Inc., Groton, Connecticut, United States of America

Daniel Ziemek

Affiliation Computational Sciences Center of Emphasis, Pfizer Inc., Cambridge, Massachusetts, United States of America

Michael T. Leininger

Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America

Ranjit Randhawa

Affiliation Computational Sciences Center of Emphasis, Pfizer Inc., Cambridge, Massachusetts, United States of America

Jianxin Yang

Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America

Tara B. Manion

Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America

Dawn E. Mather

Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America

William J. Zavadoski

Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America

Max Kuhn

Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America

Judith L. Treadway

Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America

Shelly Ann G. des Etages

Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America

E. Michael Gibbs

Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America

Nigel Greene

Affiliation Compound Safety Prediction Group, Pfizer Inc., Groton, Connecticut, United States of America

Claire M. Steppan

Affiliation Cardiovascular, Metabolic and Endocrine Diseases Research Unit, Pfizer Inc., Groton, Connecticut, United States of America

Competing Interests

The authors have read the journal's policy and have the following conflicts: The work has been funded by Pfizer Inc. as part of DGAT1 therapeutic targeting program and the authors are/were paid employee of the funder, Pfizer Inc. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: SAdE EMG CS. Performed the experiments: ML JY TM DM WZ. Analyzed the data: AE DZ ML JY MK CS. Contributed reagents/materials/analysis tools: AE DZ RR MK NG. Wrote the paper: AE DZ ML CS. Designed the experiments: DM JT.